Norway· NO-ID_578E6034-706E-4BEE-9DC2-433EA25B3A68
Epclusa
A sofosbuvir and velpatasvir product containing sofosbuvir + velpatasvir, registered in Norway by Gilead Sciences Ireland UC. The same ATC class is registered in 16 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir and velpatasvir is registered in 16 of 19 countries.
Countries holding a registration under ATC J05AP55 (sofosbuvir and velpatasvir), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 11 of them publish a price we can compare per daily dose
Sofosbuvir and velpatasvir · ATC J05AP55
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Sofosbuvir + Velpatasvir
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Norway (NO)
- ATC code
- J05AP55
- ATC class
- Sofosbuvir and velpatasvir
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_578E6034-706E-4BEE-9DC2-433EA25B3A68
- no_varenummer49123028NOK 189692.5
- gtin5391507143846
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
80 interactions on record for sofosbuvir and velpatasvir.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sofosbuvir and velpatasvir · interactions on record
80 records
- 14 severe
- 61 moderate
- 5 minor
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sofosbuvir and velpatasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainEPCLUSA 150 MG/37,5 MG GRANULADO RECUBIERTO EN SOBREGilead Sciences Ireland Unlimited Company
- FinlandEpclusaGilead Sciences Ireland UC
- United StatesEpclusaGilead Sciences, Inc.
- FranceEPCLUSA 150 mg/37,5 mg, granulés enrobés en sachetGILEAD SCIENCES IRELAND UC (IRLANDE)
- United KingdomEpclusa 150mg/37.5mg granules sachetsGilead Sciences Ltd
- SwedenEpclusa 150 mg/37,5 mg Dragerat granulat i dospåseGilead Sciences Ireland UC
- IcelandEpclusaGilead Sciences Ireland UC*
- NetherlandsEpclusa 150 mg/37,5 mg, omhuld granulaat in sachetGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Epclusa
- Liechtenstein · Epclusa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a46bc6c-31cd-4a7c-bdc2-62bdbcb21c90 GET /v1/drugs/0a46bc6c-31cd-4a7c-bdc2-62bdbcb21c90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Sofosbuvir og velpatasvir",
"merkevare_id": "ID_578E6034-706E-4BEE-9DC2-433EA25B3A68",
"name_form_strength": "Epclusa tab 400 mg/100 mg",
"prescription_group": "C"
}See everything about sofosbuvir and velpatasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.